



Submitted by: Chief Medical Officer, Myriad Genetics
Name: Thomas Slavin, MD, FACMG, DABCC
Company/Organization: Myriad Genetics Laboratories, Inc.
Address: 320 Wakara Way, Salt Lake City, UT 84108
Phone: 800-469-7423
Email: thomas.slavin@myriad.com
Date of request: July 20, 2021
NCCN Guidelines panel: Breast Cancer Treatment

Dear NCCN Breast Cancer Treatment Panel members,


On behalf of Myriad Genetics, I respectfully request your review of the following proposed modifications of the Breast Cancer Treatment guideline, Version 5.2021.

Specific change requested:

1. **BINV-N** (1 of 5): In the table, regarding the row for the 12-gene (EndoPredict) assay, in the "Predictive" column, please change "Not determined" to "Yes" for the 12-gene (EndoPredict) assay.

Rationale:

Chemopredictive justification for inclusion is based on recent publications.¹⁻² Figure shown below highlights chemo-predictive significant interaction and ability from Sestak et al. 2019¹.



FDA Clearance: Not applicable

References:

1. Sestak I, Martin M, Dubsky P, et al. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. *Breast Cancer Res Treat.* 2019; 176(2):377-386.

2. Soliman H, Flake DD, Magliocco A, et al. Predicting expected absolute chemotherapy treatment benefit in women with early-stage breast cancer using EndoPredict, an integrated 12-gene clinicomolecular assay. *JCO Precis Oncol.* 2019 3(3):1-10.

Sincerely,

A handwritten signature in black ink, consisting of several fluid, overlapping strokes that form a stylized representation of the name Thomas Slavin.

Thomas Slavin, MD, FACMG, DABCC
Chief Medical Officer
Myriad Genetics